27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Medial temporal lobe dependent cognitive functions are highly vulnerable to hypoxia in the hippocampal region, yet little is known about the relationship between the richness of hippocampal vascular supply and cognition. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Multiple biological pathways are altered and could be targeted very early in the Alzheimer's continuum. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Our results demonstrate that novel AD biomarker candidates are identified and confirmed by proteomic studies of brain tissue and biofluids, providing a rich resource for large-scale biomarker validation for the AD community. 3 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
The relationship between amyloid-β (Aβ) species and tau pathology in Alzheimer's disease (AD) is not fully understood. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The combination BBBM with MMSE is projected to increase the efficiency and value of the triage process for DMT eligibility. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Despite challenges, current literature and practice support implementation of telemedicine assessments for patients with cognitive impairment. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Genetic association studies have identified 44 common genome-wide significant risk loci for late-onset Alzheimer's disease (LOAD). 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The role of non-neuronal cells in Alzheimer's disease progression has not been fully elucidated. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
The extent of microglial heterogeneity in humans remains a central yet poorly explored question in light of the development of therapies targeting this cell type. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Protein aggregation is the hallmark of neurodegeneration, but the molecular mechanisms underlying late-onset Alzheimer's disease (AD) are unclear. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We describe a human single-nuclei transcriptomic atlas for the substantia nigra (SN), generated by sequencing approximately 17,000 nuclei from matched cortical and SN samples. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We demonstrate for the first time a link between MBI and early AD pathology in a cognitively intact elderly population, supporting the use of the MBI-C as a metric to enhance clinical trial enrolment. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In addition to Aβ and tau, ANXA5, VGF, GPM6A, and ACTZ are new signature proteins in AD EVs. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
To estimate dementia incidence rates using Australian administrative datasets and compare the characteristics of people identified with dementia across different datasets. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
Psychiatric disorders are associated with accelerated aging and enhanced risk for neurodegenerative disorders. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Presenilin1 (PSEN1) gene is the most common known genetic cause of early-onset familial Alzheimer's disease. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
In the last 20 years, research focused on developing retinal imaging as a source of potential biomarkers for Alzheimer's disease and other neurodegenerative diseases, has increased significantly. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
This case report is of a two-time stroke survivor with significant health comorbidities. 2 key findings →
Design: case report Evidence: low
Full summary, score breakdown and related studies → Original source
Social activity was associated with global cognition, perceptual speed, perceptual orientation, and episodic memory over time. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source
We observed significant increases in all-cause hospital admissions (2.53% in PD and 2.49% in AD/dementia) attributable to high PM2.5 exposure. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Cerebral amyloid angiopathy (CAA) is a common cerebrovascular disease involved in ischemic and hemorrhagic strokes, and its progression is correlated to cognitive decline. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
We present a model for digital neural impairment screening and self-assessment, which can evaluate cognitive and motor deficits for patients with symptoms of central nervous system (CNS) disorders, such as mild cognitive impairment (MCI), Parkinson's disease (PD), Huntington's disease (HD), or dementia. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent functional magnetic resonance imaging studies have demonstrated that moment-to-moment variability in the blood oxygen level-dependent (BOLD) signal is related to age differences, cognition, and symptomatic Alzheimer's disease (AD). 1 key finding →
Participants: 321 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite the presumptive common underlying neuropathology of amyloid plaques and neurofibrillary tangles, the 2 groups displayed 2 different patterns of network perturbation, each concordant with the clinical presentation and the anatomy of neurodegeneration. 2 key findings →
Participants: 14 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Transcriptome-wide association studies (TWASs) have been widely used to integrate gene expression and genetic data for studying complex traits. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →